News
News
- Novan to Present Data from SB414 Phase 1b Atopic Dermatitis Clinical Trial at 3rd Inflammatory Skin Disease Summit
12/11/2018 / 15:00 - GlobeNewswire - Novan Announces Full Top Line Results from Phase 2 Molluscum Contagiosum Clinical Trial and Decision to Move Forward with SB206 12% Once-Daily
12/10/2018 / 14:30 - GlobeNewswire - Novan Receives FDA Guidance for SB204 and Acne Indication
09/24/2018 / 22:15 - GlobeNewswire - Novan Announces Promising Clinical Results with SB414
08/20/2018 / 12:30 - GlobeNewswire - Novan Provides Business Update via 10-Q, Adopts Incentive Plan and Agrees to CEO Contract
08/08/2018 / 14:25 - GlobeNewswire - Novan to Participate in Upcoming Investor Conferences
06/13/2018 / 14:05 - GlobeNewswire - Novan Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/01/2018 / 14:05 - GlobeNewswire - SB208 Increases Daily Nail Growth Rate over Four Weeks of Treatment
05/17/2018 / 14:05 - GlobeNewswire - Novan Provides Update on SB414 Inflammatory Skin Disease Development Program
05/15/2018 / 14:10 - GlobeNewswire - Novan Advances Organization and Strengthens Leadership Team
04/12/2018 / 13:05 - GlobeNewswire
Real-time